Quoin Pharmaceuticals continues to evaluate M&A opportunities

The company said, “Quoin is committed to advancing its clinical programs and remains focused on expanding the potential indications for QRX003. The company’s efforts in initiating clinical studies in additional rare disease indications, such as Peeling Skin Syndrome, and expanding its global clinical footprint for Netherton Syndrome trials are crucial steps in Quoin’s strategy to bring new treatments to patients with serious unmet needs. The Company continues to evaluate M&A opportunities within the rare and orphan disease space as part of its long-term growth strategy.”